Compare ONC & CMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | CMG |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 42.4B |
| IPO Year | 2015 | 2005 |
| Metric | ONC | CMG |
|---|---|---|
| Price | $358.81 | $32.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 35 |
| Target Price | ★ $432.80 | $43.92 |
| AVG Volume (30 Days) | 320.8K | ★ 9.7M |
| Earning Date | 11-10-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 140.43 | 2.70 |
| EPS | 0.31 | ★ 0.55 |
| Revenue | $238,387,000.00 | ★ $11,925,601,000.00 |
| Revenue This Year | $26.33 | $9.24 |
| Revenue Next Year | $14.36 | $10.86 |
| P/E Ratio | $1,196.77 | ★ $57.59 |
| Revenue Growth | ★ 22179.16 | 5.41 |
| 52 Week Low | $253.95 | $28.10 |
| 52 Week High | $385.22 | $42.82 |
| Indicator | ONC | CMG |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 36.17 |
| Support Level | $327.01 | $31.16 |
| Resistance Level | $380.00 | $33.70 |
| Average True Range (ATR) | 6.86 | 1.15 |
| MACD | 0.75 | -0.27 |
| Stochastic Oscillator | 87.88 | 15.08 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Chipotle is a leading fast-casual, Mexican-inspired restaurant chain, generating $11.9 billion in sales across 3,983 company-operated US locations, 104 international units primarily in Canada and Europe, and 14 licensed stores largely operated in the Middle East at the end of 2025. The firm's revenue is primarily driven by food and beverage sales at its company-owned restaurants, supplemented by delivery fees generated through its first-party digital channels. Chipotle emphasizes ingredients with no artificial flavors and utilizes an efficient, assembly line service model to serve mainly customizable burritos, bowls, salads, quesadillas, and tacos.